



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



UT-155

Cat. No.:	HY-112895
CAS No.:	2031161-35-8
Molecular Formula:	C ₂₀ H ₁₅ F ₄ N ₃ O ₂
Molecular Weight:	405.35
Target:	Androgen Receptor
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 130 mg/mL (320.71 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.4670 mL	12.3350 mL	24.6700 mL
	5 mM		0.4934 mL	2.4670 mL	4.9340 mL
	10 mM		0.2467 mL	1.2335 mL	2.4670 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.17 mg/mL (5.35 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.17 mg/mL (5.35 mM); Suspended solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.17 mg/mL (5.35 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	UT-155 is a selective and potent androgen receptor (AR) antagonist, with a K _i of 267 nM for UT-155 binding to AR-LBD.
IC ₅₀ & Target	Ki: 267 nM (AR-LBD) ^[1] .
In Vitro	UT-155 binds to the AR-LBD at K _i of 267 nM. UT-155 potently inhibits the R1881-induced wildtype AR transactivation with 6-10-fold higher potency than enzalutamide. While UT-155 antagonizes both wildtype and mutant ARs comparably,

enzalutamide is weaker by two fold with the W742L mutant AR relative to the wild type AR. Treatment of LNCaP cells with UT-155 inhibits 0.1 nM R1881-induced PSA and FKBP5 gene expression between 10 and 100 nM with 5-10-fold better potency than enzalutamide^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Consistent with the anti-proliferative effects in vitro, UT-155 significantly inhibits the growth of 22RV1 xenograft by 53%, while, as expected, enzalutamide has no effect on the growth of the 22RV1 tumors. Tumor weights and PSA and the expression of AR and AR-SV are significantly lower in UT-155-treated animals^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2024 Feb 3;15(1):1038.
- bioRxiv. 2020 May.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ponnusamy S, et al. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2017 Nov 15;77(22):6282-6298.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA